Related Experiment Video
Updated: Jun 17, 2025
10:39
3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
Published on: June 2, 2014
18.2K
Causality between migraine and cardiovascular disease: a bidirectional Mendelian randomization study.
Xirui Duan1, Xiaolan Du1, Guangrong Zheng1
1Department of Radiology, Yan'an Hospital of Kunming City (Yan'an Hospital, Kunming Medical University, Yunnan Cardiovascular Hospital), Kunming, China.
The Journal of Headache and Pain
|August 12, 2024
Summary
Migraine may protect against coronary artery disease and ischemic stroke, while coronary atherosclerosis and myocardial infarction may protect against migraine. Further research is needed to understand these cardiovascular disease and migraine links.
Area of Science:
- Cardiovascular disease genetics
- Neurology
- Epidemiology
Background:
- Growing evidence suggests a link between migraine and cardiovascular disease.
- Genetic evidence for a causal relationship is limited.
- Investigating this causal association is crucial.
Purpose of the Study:
- To investigate the bidirectional causal relationship between migraine and cardiovascular disease using genetic data.
- To explore potential protective effects in either direction.
Main Methods:
- Bidirectional Mendelian randomization (MR) study.
- Utilized publicly available genome-wide association study (GWAS) summary datasets.
- Employed four MR techniques (IVW, MR-Egger, weighted median, weighted mode) and sensitivity analyses (Cochran's Q, IVW radial, LOO, MR-PRESSO).
Main Results:
- Genetically predicted migraine showed protective causal effects on coronary artery disease (OR, 0.881) and ischemic stroke (OR, 0.912).
- Coronary atherosclerosis (OR, 0.865) and myocardial infarction (OR, 0.798) demonstrated protective causal effects on migraine.
Conclusions:
- Migraine may have a protective effect on coronary artery disease and ischemic stroke.
- Coronary atherosclerosis and myocardial infarction may protect against migraine.
- Highlights the need for further research on epidemiological and genetic differences, and long-term safety monitoring for migraine medications to improve cardiovascular outcomes.
